All In Biotech

Drug Trial Radar · NCT05153226

GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 640 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

640

Actual

Start

Mar 2, 2022

Primary completion

Mar 31, 2026

Study completion Dec 2027

Sponsor

Lead sponsor
DKMS gemeinnützige GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Post-transplantation cyclophosphamide (PTCY) has become increasingly popular in the haploidentical HCT setting because it overcomes the HLA-mismatch barrier and levels GVHD risk. This advantage may also prove useful in the context of unrelated donor (UD) transplantation. GVHD prophylaxis for matched unrelated donor hematopoietic cell transplantation (alloHCT) in Europe is mainly conducted with ATG. Still, the burden of acute and chronic GVHD and especially of relapse remains high with both approaches for GVHD prevention. PTCY has not been tested against the current standard ATG for GvHD prophylaxis in large randomized trials. The goal of this trial is to compare the outcomes of PTCY and ATG for patients receiving unrelated donor PBSCT. PTCY-based prophylaxis promises to have beneficial net effects on immune reconstitution, GVHD and disease control, and thus might impact on patient survival.

Conditions

  • Graft Vs Host Disease
  • Peripheral Blood Stem Cell Transplantation
  • AML
  • MDS
  • MDS/MPN
  • CMML

Interventions

  • CyclophosphamideDrug

    50 mg/kg (AIBW) i.v. d+3, d+4 post transplant

  • ATGBiological

    10 mg/kg i.v. d-3, d-2, d-1 pre-transplant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: from randomization
  2. GVHD- and relapse-free survival (GRFS)Time frame: from HCT

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Uniklinik RWTH Aachen

    Aachen, Germany

  • Univeristätsklinikum Augsburg

    Augsburg, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, Germany

  • Universitätsklinikum Köln

    Cologne, Germany

  • St.-Johannes-Hospital Dortmund

    Dortmund, Germany

  • Universitätsklinikum Dresden

    Dresden, Germany

  • Uniklinikum Düsseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Essen (AöR)

    Essen, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Universitätsklinikum Halle (Saale)

    Halle, Germany

  • Universitätsklinikum des Saarlandes

    Homburg, Germany

  • Universitätsklinikum Jena

    Jena, Germany

  • Universitätsklinikum Schleswig-Holstein

    Kiel, Germany

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Germany

  • Universitätsmedizin Mainz

    Mainz, Germany

  • Universitätsmedizin Mannheim

    Mannheim, Germany

  • Philipps Universität Marburg

    Marburg, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • Klinikum Nürnberg Nord

    Nuremberg, Germany

  • Universitätsmedizin Rostock

    Rostock, Germany

  • Robert-Bosch-Krankenhaus

    Stuttgart, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.